Since the Nobel Prize honoured technology to produce monoclonal antibodies was invented in the 1970s, monoclonal antibodies have revolutionized medicine. And the evolution continues. Traditional monoclonal antibodies can now be modified to do their job in therapy even better. So called next generation antibody therapeutics include e. g. antibody–drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments and nanobodies. This symposium highlights some examples of promising candidates.